Who is eligible for clinical trial NCT03706690?

Participants must meet protocol criteria for Carcinoma, Non-Small-Cell Lung. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT03706690 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-05

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (NCT03706690)

A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.

Who can join: Review the eligibility criteria below.

Location: Research Site — Beijing

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

Durvalumab (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (87 Sites)

Showing the first 25 of 87 sites.

Research Site — Beijing,
Research Site — Beijing,
Research Site — Beijing,
Research Site — Beijing,
Research Site — Bengbu,
Research Site — Changchun,
Research Site — Changchun,
Research Site — Changsha,
Research Site — Chengdu,
Research Site — Chengdu,
Research Site — Chengdu,
Research Site — Chongqing,
Research Site — Fuzhou,
Research Site — Guangzhou,
Research Site — Hangzhou,
Research Site — Hangzhou,
Research Site — Hangzhou,
Research Site — Harbin,
Research Site — Linhai,
Research Site — Nanjing,
Research Site — Nanning,
Research Site — Ningbo,
Research Site — Qingdao,
Research Site — Shanghai,
Research Site — Shanghai,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Non-Small-Cell Lung

MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California

Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗